<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0504233484
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GENOTROPIN 16IU CARTRIDGE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SOMATROPIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Cartridge
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        385.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Manufacturing Belgium N.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Manufacturing Belgium N.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER SA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H01AC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>GENOTROPIN is a recombinant human growth hormone (also called somatropin). It has the same structure as natural human growth hormone which is needed for bones and muscles to grow. It also helps your fat and muscle tissues to develop in the right amounts. It is recombinant meaning it is not made from human or animal tissue.</p><p>&nbsp;</p><p>In children, GENOTROPIN is used to treat the following growth disorders:</p><ul><li>If you are not growing properly and you do not have enough of your own growth hormone.</li><li>If you have Turner syndrome. Turner syndrome is a chromosomal error in girls that can affect growth - your doctor will have told you if you have this.</li><li>If you have chronic renal insufficiency. As kidneys lose their ability to function normally, this can affect longitudinal growth.</li><li>If you have Prader-Willi syndrome (a chromosomal disorder). Growth hormone will help you grow taller if you are still growing, and will also improve your body composition. Your excessive fat will decrease and your reduced muscle mass will improve.</li><li>If you were small or too light at birth. Growth hormone can help you grow taller if you have not been able to catch up to a normal size or maintain normal growth by four years of age or later.</li></ul><p>&nbsp;</p><p>In adults, GENOTROPIN is used to treat persons with pronounced growth hormone deficiency. This can start during adult life, or it can continue from childhood.</p><p>If you have been treated with GENOTROPIN for growth hormone deficiency during childhood, your growth hormone status will be retested after completion of longitudinal growth. If severe growth hormone deficiency is confirmed, your doctor will propose continuation of GENOTROPIN treatment.</p><p>&nbsp;</p><p>You should only be given this medicine by a doctor who has experience with growth hormone treatment and who has confirmed your diagnosis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use GENOTROPIN and tell your doctor if</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic (hypersensitive) to somatropin or any of the other ingredients of GENOTROPIN.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have an active tumour (cancer). Tumours must be inactive and you must have finished your anti-tumour treatment before starting your treatment with GENOTROPIN.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are seriously ill (for example, complications following open heart surgery, abdominal surgery, acute respiratory failure, accidental trauma or similar conditions). If you are about to have, or have had, a major operation, or if you are admitted to hospital for any reason,<strong> </strong>tell your doctor and remind the other doctors you are seeing that you use growth hormone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GENOTROPIN has been prescribed to stimulate growth but you have already stopped growing (closed epiphyses).</p><p>&nbsp;</p><p><strong>Take special care with GENOTROPIN and tell your doctor if any of the following statements applies to you</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are at risk of developing diabetes, your doctor will need to monitor your blood glucose level during treatment with GENOTROPIN.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have diabetes, you should closely monitor your blood glucose level during treatment with GENOTROPIN and discuss the results with your doctor to determine whether you need to change the dose of your diabetes medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After starting GENOTROPIN treatment, some patients may need to start thyroid hormone replacement.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are receiving treatment with thyroid hormones, it may be necessary to adjust your thyroid hormone dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking growth hormone to stimulate growth and walk with a limp, or if you start to limp during your growth hormone treatment due to pain in your hip, you should inform your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you develop raised intracranial pressure (with symptoms such as severe headache, visual disturbances or vomiting), you should inform your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor confirms that you have developed inflammation of the muscles near the injection site because of the preservative metacresol, you should use a GENOTROPIN product which does not contain metacresol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are receiving GENOTROPIN for growth hormone deficiency following a previous tumour&nbsp;(cancer), you should be examined regularly for recurrence of the tumour or any other cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience worsening abdominal pain, you should inform your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Experience in patients above 80 years of age is limited. Elderly persons may be more sensitive to the action of GENOTROPIN, and therefore may be more prone to develop side effects.</p><p>&nbsp;</p><p><strong>Children with chronic renal (kidney) insufficiency:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor should examine your kidney function and your growth rate before you start &nbsp;treatment. Medical treatment for your kidney condition should be continued. &nbsp;treatment should be stopped in case of kidney transplantation.</p><p>&nbsp;</p><p><strong>Children with Prader-Willi syndrome:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will give you diet restrictions to follow to control your weight.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will assess you for signs of upper airway obstruction, sleep apnoea (interruption of breathing during sleep) or respiratory infection before you start treatment with GENOTROPIN.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During treatment, if you show signs of upper airway obstruction (including starting to snore or worsening of snoring), your doctor will need to examine you and may discontinue your treatment with GENOTROPIN.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During treatment, your doctor will check you for signs of scoliosis, a type of spinal deformity.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During treatment, if you develop a lung infection, tell your doctor so that he can treat the infection.</p><p>&nbsp;</p><p><strong>Children born small or too light at birth:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you were small or too light at birth and are aged between 9 and 12 years, ask your doctor for specific advice relating to puberty and treatment with this product.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will check your blood glucose and insulin levels before the start of treatment and every year during treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment should be continued until you have stopped growing.</p><p>&nbsp;</p><p><strong>Other medicines and </strong></p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before using GENOTROPIN.</p><p>&nbsp;</p><p>If you have a replacement therapy with glucocorticoids, you should consult your doctor regularly, as you may require an adjustment of your glucocorticoid dose.</p><p>&nbsp;</p><p>You should tell your doctor if you are using:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat diabetes,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thyroid hormones,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; synthetic adrenal hormones (corticosteroids),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oestrogen taken orally or other sex hormones,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin (a medicine that weakens the immune system after transplantation),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to control epilepsy (anticonvulsants).</p><p>Your doctor may need to adjust the dose of these medicines or the dose of GENOTROPIN.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>You should not use GENOTROPIN if you are pregnant, think you may be pregnant or are planning to have a baby.</p><p>&nbsp;</p><p>Ask your doctor for advice before using this medicine while breast-feeding.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p><strong>GENOTROPIN contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &ldquo;sodium‑free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Recommended dosage</strong></p><p>The dose<strong> </strong>depends on your size, the condition for which you are being treated and how well growth hormone works for you. Everyone is different. Your doctor will advise you about your individualised dose of GENOTROPIN in milligrams (mg) from either your body weight in kilograms (kg) or your body surface area calculated from your height and weight in square metres (m<sup>2</sup>), as well as your treatment schedule. Do not change the dosage and treatment schedule without consulting your doctor.</p><p>&nbsp;</p><p>Children with growth hormone deficiency:</p><p>0.025-0.035 mg/kg body weight per day or 0.7-1.0 mg/m<sup>2 </sup>body surface area per day. Higher doses may be used. When growth hormone deficiency continues into adolescence, GENOTROPIN treatment should be continued until completion of physical development.</p><p>&nbsp;</p><p>Children with Turner syndrome:</p><p>0.045-0.050 mg/kg body weight per day or 1.4 mg/m<sup>2</sup> body surface area per day.</p><p>&nbsp;</p><p>Children with chronic renal (kidney) insufficiency:</p><p>0.045-0.050 mg/kg body weight per day or 1.4 mg/m<sup>2</sup> body surface area per day. Higher doses may be necessary if the rate of growth is too low. Dosage adjustment may be necessary after 6&nbsp;months of treatment.</p><p>&nbsp;</p><p>Children with Prader-Willi syndrome:</p><p>0.035 mg/kg body weight per day or 1.0 mg/m<sup>2</sup> body surface area per day. The daily dosage should not exceed 2.7 mg. Treatment may not be used in children who have almost stopped growing after puberty.</p><p>&nbsp;</p><p>Children born smaller or lighter than expected and with growth disorder:</p><p>0.035 mg/kg body weight per day or 1.0&nbsp;mg/m<sup>2</sup> body surface area per day. It is important to continue treatment until final height is reached. Treatment should be discontinued after the first year if you are not responding to the treatment or if you have reached your final height and stopped growing.</p><p>&nbsp;</p><p>Adults with growth hormone deficiency:</p><p>If you continue using GENOTROPIN after treatment during childhood, you should start with a dose of 0.2-0.5&nbsp;mg per day. This dosage will be gradually increased or decreased according to blood test results as well as clinical response and side effects.</p><p>If your growth hormone deficiency starts during adult life, you should start with a dose of 0.15-0.3&nbsp;mg per day. This dosage will be gradually increased according to blood test results as well as clinical response and side effects. The daily maintenance dose seldom exceeds 1.0&nbsp;mg per day. Women may require higher doses than men. Dose adjustment should be reassessed every 6&nbsp;months. In persons above 60&nbsp;years, treatment should be initiated at a dose of 0.1&ndash;0.2&nbsp;mg per day and should be slowly increased according to individual requirements. The minimum effective dose should be used. The daily maintenance dose seldom exceeds 0.5&nbsp;mg per day. Please follow the instructions given to you by your doctor.</p><p>&nbsp;</p><p><strong>Injecting GENOTROPIN</strong></p><p>GENOTROPIN is intended for subcutaneous use. This means that it is injected through a short injection needle into the fatty tissue just under your skin. Your doctor should have already shown you how to use GENOTROPIN. Always inject GENOTROPIN exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist for help.</p><p>&nbsp;</p><p><strong>The instructions for use of the GENOTROPIN two-chamber cartridge with the GENOTROPIN Pen are provided with your device.</strong></p><p><strong>Refer to the instructions for use before using your medicine.</strong></p><p>&nbsp;</p><p>When using a pen injection device, the needle must be screwed on the device before mixing. A brand new needle must be used for each injection. Needles must not be re-used.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Preparing the injection:</p><p>You can take your GENOTROPIN out of the refrigerator half an hour before your injection. This lets it warm up slightly and can make your injections more comfortable.</p><p>&nbsp;</p><p>GENOTROPIN in a two-chamber cartridge contains both the growth hormone and the dissolving liquid and it is to be used in a GENOTROPIN device. The growth hormone and the dissolving liquid in the two‑chamber cartridge can be mixed together by screwing the two parts of the GENOTROPIN Pen device together.</p><p>&nbsp;</p><p>For the two-chamber cartridge, dissolve the powder by gently tipping it back and forth until the powder is completely dissolved.</p><p>&nbsp;</p><p>When you are mixing your GENOTROPIN, DO NOT SHAKE the solution. Mix it gently. Shaking the solution could cause the formation of foam and damage the active substance of your growth hormone. Check the solution and do not inject it if the solution is cloudy or has particles in it.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injecting GENOTROPIN:</p><p>Remember to wash your hands and clean your skin first.</p><p>&nbsp;</p><p>Inject your growth hormone at about the same time every day. Bedtime is a good time because it is easy to remember. It is also natural to have a higher level of growth hormone at night.</p><p>&nbsp;</p><p>Most people do their injections into their thigh or their bottom. Do your injection in the place you have been shown by your doctor. Fatty tissue of the skin can shrink at the site of injection. To avoid this, use a different place for your injection each time. This gives your skin and the area under your skin time to recover from one injection before it gets another one in the same place.</p><p>&nbsp;</p><p>Remember to put your GENOTROPIN back in the refrigerator straight after the injection.</p><p>&nbsp;</p><p><strong>If you use more GENOTROPIN than you should</strong></p><p>If you use too much GENOTROPIN, contact your doctor, pharmacist immediately.</p><p>Your blood sugar level could become too low and then too high. You might feel shaky, sweaty, sleepy or &ldquo;not yourself&rdquo;, and you might faint.</p><p>&nbsp;</p><p><strong>If you forget to use GENOTROPIN</strong></p><p>Do not take a double dose to make up for a forgotten dose.</p><p>It is preferable to use your growth hormone regularly. If you forget to use a dose, carry out the next injection at the usual time the next day. Keep a note of any missed injections and tell your doctor at your next check-up.</p><p>&nbsp;</p><p><strong>If you stop using GENOTROPIN</strong></p><p>Ask for advice from your doctor before you stop using GENOTROPIN.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, GENOTROPIN can cause side effects, although not everybody gets them.</p><p>The very common and common side effects in adults may start within the first months of treatment and may either stop spontaneously or if your dose is reduced.</p><p>&nbsp;</p><p><strong>Very common side effects (may affect more than 1 in 10 people) include:</strong></p><p><strong>&nbsp;</strong></p><p><strong>In adults:</strong></p><ul><li>Joint pain.</li><li>Water retention (which shows as puffy fingers or swollen ankles).</li></ul><p>&nbsp;</p><p><strong>Common side effects (may affect up to 1 in 10 people) include:</strong></p><p>&nbsp;</p><p><strong>In children:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Temporary reddening, itchiness or pain at the injection site.</p><p>&nbsp;</p><p><strong>In adults:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness/tingling.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain or burning sensation in the hands or underarms (known as carpal tunnel syndrome).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stiffness in the arms and legs, muscle pain.</p><p>&nbsp;</p><p><strong>Uncommon side effects (may affect up to 1 in 100 </strong><strong>people) include:</strong></p><p><strong>&nbsp;</strong></p><p><strong>In children:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leukaemia (cases have been reported in a small number of growth hormone deficiency patients, some of whom have been treated with somatropin. However, there is no evidence that leukaemia incidence is increased in growth hormone recipients without predisposing factors).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased intracranial pressure (which causes symptoms such as severe headache, visual disturbances or vomiting).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness/tingling.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raised itchy bumps on the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast enlargement in males (gynaecomastia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Water retention (which shows as puffy fingers or swollen ankles, for a short time at the start of treatment).</p><p>&nbsp;</p><p><strong>In adults:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast enlargement in males (gynaecomastia).</p><p>&nbsp;</p><p><strong>Not known: frequency cannot be estimated from the available data</strong></p><ul><li>Type 2 diabetes.</li><li>Facial swelling.</li><li>Headache.</li><li>Decrease in the levels of cortisol in your blood.</li></ul><p>&nbsp;</p><p><strong>In children:</strong></p><ul><li>Stiffness in the arms and legs.</li></ul><p>&nbsp;</p><p><strong>In adults:</strong></p><ul><li>Increased intracranial pressure (which causes symptoms such as severe headache, visual disturbances or vomiting).</li><li>Rash.</li><li>Itching.</li><li>Raised itchy bumps on the skin.</li><li>Reddening, itchiness or pain at the injection site.</li></ul><p>&nbsp;</p><p>Formation of antibodies to the injected growth hormone can occur, but these antibodies do not seem to stop the growth hormone from working.</p><p>&nbsp;</p><p>The skin around the injection area can get uneven or lumpy, but this should not happen if you carry out the injection in a different place each time.</p><p>&nbsp;</p><p>For GENOTROPIN 5.3 mg:&nbsp; A very rare side effect that can occur because of the preservative metacresol is inflammation of the muscles near the injection site. If your doctor confirms that you have developed this side effect, you should use a GENOTROPIN product which does not contain metacresol.</p><p>&nbsp;</p><p>There have been rare cases of sudden death in patients with Prader-Willi syndrome. However, no link has been established between these cases and treatment with GENOTROPIN.</p><p>&nbsp;</p><p>Slipped capital femoral epiphysis and Legg-Calve-Perthes disease may be considered by your doctor if discomfort or pain in the hip or knee is experienced whilst being treated with GENOTROPIN.</p><p>&nbsp;</p><p>Other possible side effects during treatment with growth hormone may include the following: you (or your child) may experience a high blood sugar or reduced levels of thyroid hormone. This can be tested by your doctor and if necessary your doctor will prescribe the adequate treatment. Rare cases of inflammation of the pancreas have been reported in patients treated with growth hormone.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report side effect(s): </strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia: </strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>The </strong><strong>National Pharmacovigilance Centre (NPC):</strong></p><ul><li>Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States:</strong><br />&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton as MM/YYYY. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p><u>Before reconstitution</u></p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Keep the two-chamber cartridge in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Before opening, the product may be taken out of the refrigerator, without being put back, for a maximum period of 1 month at a temperature not above 25&deg;C, but after this period it must be discarded.</p><p>&nbsp;</p><p><u>After reconstitution</u></p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C) for up to 28 days. Do not freeze. Keep the two-chamber cartridge in the Pen box, in order to protect from light.</p><p>&nbsp;</p><p>Do not use this medicine if you notice particles or if the solution is cloudy.</p><p>&nbsp;</p><p>Do not freeze or expose GENOTROPIN to frost. If it freezes, do not use it.</p><p>&nbsp;</p><p>Never throw away needles or partly used or empty cartridges with your ordinary rubbish. When you have finished with a needle, you must discard it carefully in a suitable sharps container so that no-one will be able to use it or prick themselves on this needle.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is somatropin*.</li><li>One cartridge contains 5.3 mg of somatropin*.</li><li>After reconstitution, the concentration of somatropin* is 5.3 mg per mL.</li><li>The other ingredients in the powder are: glycine (E640), mannitol (E421), sodium dihydrogen phosphate anhydrous (E339), and disodium phosphate anhydrous (E339) (see section 2 &ldquo;GENOTROPIN contains sodium&rdquo;).</li><li>The ingredients in the solvent are: water for injections, mannitol (E421) and metacresol.</li></ul><p><strong>&nbsp;</strong></p><p>* produced in <em>Escherichia coli </em>cells by recombinant DNA technology</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                GENOTROPIN 5.3 mg is a powder and solvent for solution for injection, in a two-chamber cartridge containing the powder in one section and the solvent in the other (5.3 mg/mL). Pack size of 1 cartridge.

The powder is white and the solvent is clear.

	You can use the cartridges in a specific pen injection device for GENOTROPIN. GENOTROPIN cartridges are colour coded and must be used with the matching colour coded GENOTROPIN Pen to give the correct dose: the GENOTROPIN 5.3 mg cartridge (blue) must be used with the GENOTROPIN Pen 5.3 (blue). 
	
	The instructions for use of the device are enclosed in the device package. Ask your doctor for an injection device if you do not already have one.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing </strong><strong>Authorisation Holder</strong></p><p>Pfizer SA, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs Sint-Amands, Belgium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">جينوتروبين هو هرمون نمو بشري مؤتلف (ويطلق عليه كذلك سوماتروبين). يماثل تركيبه تركيب هرمون النمو البشري الطبيعي اللازم لنمو العظام والعضلات. كما يساعد على نمو الأنسجة الدهنية والعضلية الخاصة بك بالكميات المناسبة. وهو مأشوب (مؤتلف)، مما يعني أنه غير مصنوع من الأنسجة البشرية أو الحيوانية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في الأطفال، يُستخدم جينوتروبين لعلاج اضطرابات النمو التالية:</p><ul><li dir="RTL">إذا كنت لا تنمو بشكل صحيح ولا يوجد في جسدك ما يكفي من هرمون النمو.</li><li dir="RTL">إذا كنت مصابًا بمتلازمة ترنر. متلازمة ترنر هي اضطراب كروموسومي يصيب الفتيات ويمكنه أن يؤثر على النمو - سيكون الطبيب الخاص بك قد أخبرك إذا كنت مصابة بهذه المتلازمة.</li><li dir="RTL">إذا كنت مصابًا بقصور كلوي مزمن. حين تفقد الكليتان قدرتهما على العمل بشكل طبيعي، يمكن أن يؤثر ذلك على النمو الطولي.</li><li dir="RTL">إذا كنت مصابًا بمتلازمة برادر-ويلي (اضطراب كروموسومي). سيساعدك هرمون النمو على زيادة الطول إذا كنت لا تزال في طور النمو، كما سيعمل على تحسين تركيبة جسمك. ستنخفض نسبة الدهون الزائدة في جسمك وستتحسن حالة الانخفاض في كتلتك العضلية.</li><li dir="RTL">إذا كنت مولودًا بجسم ضئيل أو إذا كان وزنك خفيفًا جدًا عند الولادة. يمكن لهرمون النمو أن يساعد على زيادة طولك إذا لم تتمكن من بلوغ معدل النمو الطبيعي أو الحفاظ عليه بعد بلوغك أربعة أعوام أو أكثر من العمر.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم جينوتروبين في حالة البالغين لعلاج المرضى المصابين بنقص ملحوظ في هرمون النمو. قد يستمر ذلك من مرحلة الطفولة وقد يبدأ بعد البلوغ.</p><p dir="RTL">إذا كان قد سبق لك العلاج بجينوتروبين لعلاج نقص هرمون النمو أثناء طفولتك، فسوف تتم إعادة فحص حالة هرمون النمو لديك بعد اكتمال النمو الطولي. إذا تم التأكد من إصابتك بنقص حاد في هرمون النمو، فسوف يقترح طبيبك الاستمرار في العلاج بجينوتروبين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي أن تتلقى هذا الدواء فقط بناءً على وصف طبيب ذي خبرة في علاج هرمون النمو ومتأكد من تشخيص حالتك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>وانع استعمال جينوتروبين</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تشكو من حساسية (فرط التحسس) لسوماتروبين أو لأي من مكونات جينوتروبين الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بورم نشط (سرطان). يجب أن تكون أي أورام تعاني منها غير نشطة وأن تكون قد أنهيت علاجك المضاد للأورام قبل بدء العلاج بجينوتروبين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مريضًا بشكل خطير (مثل المضاعفات التالية لجراحة القلب المفتوح أو جراحات البطن أو القصور الرئوي الحاد أو الإصابات العرضية أو حالات مشابهة). إذا كنت على وشك الخضوع، أو قد خضعت بالفعل، لعملية جراحية خطيرة، أو إذا تم إدخالك إلى المستشفى لأي سبب كان،<strong> </strong>أخبر طبيبك وأخطر الأطباء الآخرين المشرفين على حالتك بأنك تتلقى هرمون النمو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان جينوتروبين قد وصف لك لتحفيز نمو جسمك لكن جسمك قد توقف بالفعل عن النمو (انغلاق المشاش (أطراف العظام)).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توخ الحذر الخاص عند استخدام جينوتروبين وأخبر طبيبك إذا كان أي من الحالات التالية تنطبق عليك</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت معرضًا لخطر الإصابة بداء السكري، فسيحتاج طبيبك لمراقبة مستوى الجلوكوز في دمك أثناء العلاج بجينوتروبين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بداء السكري، ينبغي عليك مراقبة مستوى الجلوكوز في دمك عن كثب أثناء العلاج بجينوتروبين ومناقشة النتائج مع طبيبك لتحديد ما إذا كنت في حاجة لتغيير جرعات أدوية داء السكري التي تتلقاها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد بدء العلاج بجينوتروبين، قد يحتاج بعض المرضى إلى بدء علاج تعويضي لهرمون الغدة الدرقية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إّذا كنت تتلقى علاجًا بهرمونات الغدة الدرقية، فقد يكون من الضروري تعديل جرعات هرمون الغدة الدرقية التي تتلقاها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول هرمون النمو لتحفيز نمو جسمك وكنت تعرج، أو بدأت تعاني من العرج أثناء علاجك بهرمون النمو بسبب إحساسك بألم في الفخذ، فينبغي عليك إبلاغ طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي عليك إبلاغ طبيبك إذا ما أصبت بزيادة في الضغط داخل الجمجمة (مصحوبة بأعراض مثل الصداع الشديد أو اضطرابات الرؤية أو القيء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ما أكّد طبيبك إصابتك بالتهاب في العضلات بالقرب من موضع الحقن بسبب المادة الحافظة التي تُسمى ميتاكريزول، ينبغي عليك استخدام نوع من جينوتروبين لا يحتوي على الميتاكريزول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى جينوتروبين لعلاج نقص في هرمون النمو بعد علاجك&nbsp; من ورم (سرطان) سابق، ينبغي عليك الخضوع لفحص دوري للتأكد من عدم ظهور الورم مجددًا أو أي سرطان آخر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تعاني من ألم في البطن يزداد سوءًا، ينبغي أن تبلغ طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا توجد خبرة كافية عن الاستخدام لدى المرضى الذين تزيد أعمارهم عن ٨٠ عامًا. قد يكون كبار السن أكثر حساسية لتأثير جينوتروبين، ولذلك فقد يكونون أكثر عرضة للإصابة بالآثار الجانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال المصابون بقصور كلوي مزمن:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي على طبيبك فحص وظائف الكلى لديك ومعدل النمو الخاص بك قبل بدء العلاج. ينبغي مواصلة العلاج الطبي الخاص بمرض الكلى الذي تعاني منه. ينبغي إيقاف العلاج في حالة الخضوع لعملية زراعة الكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال المصابون بمتلازمة برادر-ويلي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيفرض طبيبك بعض القيود الغذائية اللازم اتباعها للسيطرة على وزنك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم طبيبك بإخضاعك لتقييم للكشف عن علامات انسداد المسالك الهوائية العلوية أو انقطاع النفس النومي (انقطاع التنفس أثناء النوم) أو العدوى التنفسية قبل بدء العلاج بجينوتروبين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ما ظهرت عليك أي علامات لانسداد المسالك الهوائية العلوية (بما في ذلك بدء المعاناة من الشخير أو أن تزداد حالة الشخير سوءًا) أثناء العلاج، فسيحتاج طبيبك أن يقوم بفحصك وقد يوقف علاجك بجينوتروبين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء العلاج، سيقوم طبيبك بفحص حالتك للبحث عن أي علامات للإصابة بالجنف، وهو تشوه يصيب العمود الفقري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ما أصبت بعدوى في الرئة أثناء العلاج، فأخبر طبيبك حتى يتمكن من علاج العدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال المولودون بأجسام ضئيلة أو الذين كانت أوزانهم خفيفة جدًا عند الولادة:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان جسمك ضئيلًا أو وزنك خفيفًا جدًا عند ولادتك وكنت تبلغ ما بين ٩ و١٢ عامًا من العمر، اطلب من طبيبك توجيهًا خاصًا حول البلوغ والعلاج باستخدام هذا المنتج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم طبيبك بتفقد مستويات الجلوكوز والإنسولين في دمك قبل بدء العلاج، ثم سنويًا أثناء العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي أن يستمر العلاج حتى تتوقف عن النمو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول الأدوية الأخرى مع هذا الدواء</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أي أدوية أخرى، بما في ذلك تلك التي تُصرف دون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال جينوتروبين</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل استخدام جينوتروبين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتلقى علاجًا بديلًا باستخدام القشرانيات السكرية، ينبغي عليك استشارة طبيبك بانتظام، حيث قد يلزمك تعديل جرعة القشرانيات السكرية التي تتلقاها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عليك إبلاغ طبيبك إذا كنت تستخدم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج مرض السكري،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمونات الغدة الدرقية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمونات الغدة الكظرية الصناعية (الكورتيكوستيرويدات)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإستروجين الذي يتم تناوله عن طريق الفم أو الهرمونات الجنسية الأخرى،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سايكلوسبورين (دواء يضعف الجهاز المناعي بعد عمليات الزرع)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية للتحكم في الصرع (مضادات الاختلاج/التشنجات).</p><p dir="RTL">قد يحتاج طبيبك إلى تعديل جرعات هذه الأدوية أو جرعة جينوتروبين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">لا ينبغي عليكِ استخدام جينوتروبين إذا كنت حاملًا أو تعتقدين أنكِ حامل أو كنت تخططين للإنجاب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">استشيري طبيبك قبل استخدام هذا الدواء أثناء الرضاعة الطبيعية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">استشيري طبيبكِ أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات جينوتروبين</strong></p><p dir="RTL"><strong>يحتوي جينوتروبين على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ١ مللي مول من الصوديوم (٢٣ مجم) لكل جرعة، أي يُعد بشكل أساسي &quot;خاليًا من الصوديوم&quot;.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الجرعة الموصى بها</strong></p><p dir="RTL">تعتمد الجرعة على حجمك والحالة المرضية التي تُعالج منها وعلى مدى فاعلية هرمون النمو في حالتك. يختلف الأمر من فرد لآخر. سوف يشير عليك طبيبك بمقدار جرعة جينوتروبين المخصصة لك بالملليجرام (مجم) وفقًا إما لوزن جسمك بالكيلوجرامات (كجم) أو لمساحة سطح جسمك بالأمتار المربعة (م<sup>٢</sup>) المحسوبة استنادًا إلى طولك ووزنك، إلى جانب نظام العلاج. لا تقم بتغيير الجرعة أو نظام العلاج دون استشارة طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأطفال المصابون بنقص هرمون النمو:</p><p dir="RTL">٠,٠٢٥-٠,٠٣٥ مجم/كجم من وزن الجسم يوميًا أو ٠,٧-١,٠ مجم/م<sup>٢</sup> من مساحة سطح الجسم يوميًا. ويمكن استخدام جرعات أعلى. عند استمرار نقص هرمون النمو خلال فترة المراهقة، ينبغي أن يستمر العلاج بجينوتروبين حتى اكتمال النمو الجسدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأطفال المصابون بمتلازمة ترنر:</p><p dir="RTL">٠,٠٤٥-٠,٠٥٠ مجم/كجم من وزن الجسم يوميًا أو ١,٤ مجم/م<sup>٢</sup> من مساحة سطح الجسم يوميًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأطفال المصابون بقصور كلوي مزمن:</p><p dir="RTL">٠,٠٤٥-٠,٠٥٠ مجم/كجم من وزن الجسم يوميًا أو ١,٤ مجم/م<sup>٢</sup> من مساحة سطح الجسم يوميًا. قد يلزم العلاج بجرعات أعلى في حالة الانخفاض الشديد لمعدل النمو. قد يلزم تعديل الجرعات بعد ٦ أشهر من العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأطفال المصابون بمتلازمة برادر-ويلي:</p><p dir="RTL">٠,٠٣٥ مجم/كجم من وزن الجسم يوميًا أو ١,٠ مجم/م<sup>٢</sup> من مساحة سطح الجسم يوميًا. ينبغي ألا تتخطى الجرعة اليومية ٢,٧ مجم. قد لا يتم استخدام العلاج مع الأطفال الذين توقفوا تقريبًا عن النمو بعد سن البلوغ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأطفال المولودون وأجسامهم أكثر ضآلة أو أخف وزنًا من المتوقع والمصابون باضطراب في النمو:</p><p dir="RTL">٠,٠٣٥ مجم/كجم من وزن الجسم يوميًا أو ١,٠ مجم/م<sup>٢</sup> من مساحة سطح الجسم يوميًا. من المهم مواصلة العلاج حتى الوصول إلى الطول النهائي. ينبغي إيقاف العلاج بعد العام الأول إذا كنت لا تستجيب للعلاج أو إذا وصلت لطولك النهائي وتوقف نموك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">البالغون المصابون بنقص هرمون النمو:</p><p dir="RTL">إذا ما واصلت استخدام جينوتروبين كاستمرار لعلاجك أثناء الطفولة، فينبغي عليك البدء بجرعة قدرها ٠,٢-٠,٥ مجم يوميًا. سيتم زيادة أو خفض هذه الجرعة تدريجيًا وفقًا لنتائج اختبارات الدم إلى جانب الاستجابة السريرية (الإكلينيكية) والآثار الجانبية.</p><p dir="RTL">إذا بدأت إصابتك بنقص هرمون النمو بعد البلوغ، فينبغي عليك البدء بجرعة قدرها ٠,١٥-٠,٣ مجم يوميًا. ستتم زيادة أو خفض هذه الجرعة تدريجيًا وفقًا لنتائج اختبارات الدم إلى جانب الاستجابة السريرية والآثار الجانبية. نادرًا ما تتخطى الجرعة اليومية ١,٠ مجم يوميًا. قد تحتاج النساء إلى جرعات أعلى من الرجال. ينبغي إعادة تقييم التعديلات في الجرعة كل ٦ أشهر. بالنسبة للأشخاص الذين تزيد أعمارهم عن ٦٠ عامًا، ينبغي بدء العلاج بجرعة قدرها ٠,١ - ٠,٢ مجم يوميًا، وزيادتها ببطء حسب الاحتياجات الفردية. ينبغي استخدام أقل جرعة فعالة ممكنة. نادرًا ما تتخطى الجرعة اليومية ٠,٥ مجم يوميًا. يرجى اتّباع التعليمات التي يعطيها لك طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حَقن جينوتروبين</strong></p><p dir="RTL">جينوتروبين مخصص للاستخدام تحت الجلد. يعني ذلك أنه يتم حقنه باستخدام إبرة حقن قصيرة في النسيج الدهني الواقع مباشرةً تحت جلدك. ينبغي أن يكون طبيبك قد أطلعك بالفعل على كيفية استخدام جينوتروبين. التزم دومًا بحقن جينوتروبين تمامًا كما أطلعك طبيبك. إذا لم تكن متأكدًا مما عليك فعله، فاطلب من طبيبك أو الصيدلي مساعدتك.</p><p dir="RTL">&nbsp;<strong>&nbsp;</strong></p><p dir="RTL"><strong>ستجد تعليمات خرطوشة جينوتروبين ذات الحجرتين مع قلم جينوتروبين مرفقة مع الأدوات الخاصة بك.</strong></p><p dir="RTL"><strong>يُرجى الرجوع إلى تعليمات الاستخدام قبل استخدام دوائك.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">عند استخدام قلم حقن ، يجب تركيب الإبرة في الأداة قبل الخلط. يجب استخدام إبرة جديدة كليًا لكل عملية حقن. يجب عدم إعادة استخدام الإبر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحضير الحقنة:</p><p dir="RTL">يمكنك إخراج جينوتروبين الخاص بك من المُبرِد قبل عملية الحقن بنصف ساعة. يسمح ذلك بأن يدفأ الدواء قليلًا، ويمكن أن يجعل من عملية الحقن أكثر راحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي جينوتروبين في الخرطوشة ذات الحجرتين على هرمون النمو والسائل المذيب، وهو معد للاستخدام في أداة مُخصصة لجينوتروبين. يمكن خلط هرمون النمو والسائل المذيب في الخرطوشة ذات الحجرتين معًا عن طريق لف جزئي قلم جينوتروبين معًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة للخرطوشة ذات الحجرتين، قم بإذابة المسحوق عن طريق إمالتهما للأمام والخلف حتى يذوب المسحوق تمامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">خلال خلطك لجينوتروبين الخاص بك، لا تقم برَجّ المحلول. اخلطه برفق. إن رجّ المحلول يمكن أن يسبب تكوّن رغوة ويُتلف المادة الفعالة لهرمون النمو الخاص بك. افحص المحلول ولا تقم بحقنه إذا كان معكرًا أو يحتوي على جسيمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حَقن جينوتروبين:</p><p dir="RTL">تذكر أن تغسل يديك وأن تنظف الجلد في موضع الحقن أولًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قم بحقن هرمون النمو الخاص بك في الوقت نفسه تقريبًا من كل يوم. يُعد الوقت السابق للخلود إلى النوم وقتًا مناسبًا حيث يسهل تذكره. كما أنه من الطبيعي أن ترتفع مستويات هرمون النمو أثناء الليل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يقوم أغلب الناس بالحقن في فخذهم أو أردافهم. قم بالحقن في المكان الذي وضحه لك طبيبك. يمكن أن يتقلص النسيج الدهني للجلد في موضع الحقن. لتجنب حدوث ذلك، احقن في منطقة مختلفة في كل مرة. سيتيح ذلك لجلدك وللمنطقة تحت جلدك الوقت للتعافي من عملية الحقن قبل الحقن في نفس المنطقة مجددًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تذكر أن تعيد جينوتروبين إلى المُبرد بعد الحقن مباشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا استخدمت كمية أكثر مما ينبغي</strong></p><p dir="RTL">إذا استخدمت جرعة زائدة من جينوتروبين ، فاتصل بطبيبك أو الصيدلي على الفور.</p><p dir="RTL">فقد يصبح مستوى السكر في الدم منخفضًا للغاية ثم يرتفع بشدة. قد تصاب بالارتجاف أو التعرّق أو النعاس أو بأنك &quot;لست على طبيعتك&quot;، وقد تتعرض للإغماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة جينوتروبين</strong></p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p dir="RTL">من المحبذ أن تداوم على استخدام هرمون النمو بانتظام. إذا ما نسيت استخدام إحدى الجرعات، فقم بحقن الجرعة التالية في الوقت المعتاد من اليوم التالي. قم بتسجيل أي جرعات تم تفويتها وأخبر طبيبك بها في موعد الفحص التالي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول جينوتروبين</strong></p><p dir="RTL">اطلب المشورة من طبيبك قبل توقفك عن استخدام جينوتروبين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، قد يتسبب جينوتروبين في حدوث أعراض جانبية، ولكنها لا تحدث للجميع.</p><p dir="RTL">قد تبدأ هذه الأعراض الجانبية الشائعة جدًا والشائعة لدى البالغين أثناء الأشهر الأولى من العلاج، وقد تتوقف بشكل تلقائي أو إذا تم تقليل الجرعة التي تتلقاها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة جدًا (</strong><strong>قد</strong><strong> تصيب أكثر من شخص واحد بين كل </strong>١٠<strong> أشخاص) تتضمن:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>في البالغين:</strong></p><ul><li dir="RTL">ألم في المفاصل.</li><li dir="RTL">احتباس الماء (الذي يظهر في صورة تورم الأصابع أو الكاحلين).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة (قد تصيب ما يصل إلى شخص واحد بين كل </strong>١٠<strong> أشخاص) تتضمن:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>في الأطفال:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار أو حكة أو ألم مؤقت في موضع الحقن.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>في البالغين:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خدر/وخز.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالألم أو بالحرقان في اليدين أو الإبطين (يُعرف ذلك باسم متلازمة النفق الرسغي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب في الذراعين والساقين، ألم في العضلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية غير الشائعة (قد تصيب ما يصل إلى شخص واحد بين كل </strong>١٠٠<strong> شخص)</strong><strong> تتضمن:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>في الأطفال:</strong> سرطان الدم (تم الإبلاغ عن حالات في عدد قليل من المرضى المصابين بنقص هرمون النمو، وقد تم علاج بعضهم باستخدام سوماتروبين. إلا أنه لا يوجد دليل على زيادة معدل حدوث سرطان الدم لدى متلقيّ هرمون النمو دون وجود عوامل مهيئة لذلك).</p><ul><li dir="RTL">زيادة الضغط داخل الجمجمة (مما يتسبب في ظهور أعراض كالصداع الشديد أو اضطرابات في الرؤية أو القيء).</li><li dir="RTL">خدر/وخز.</li><li dir="RTL">طفح جلدي.</li><li dir="RTL">حكة.</li><li dir="RTL">نتوءات بارزة مثيرة للحكة على الجلد.</li><li dir="RTL">ألم في العضلات.</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الثدي في الرجال (التثدي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس الماء في الجسم (يظهر في صورة انتفاخ الأصابع أو تورم الكاحلين، لفترة قصيرة في بداية العلاج).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في البالغين:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الثدي في الرجال (التثدي).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير معروفة: لا يمكن تقدير معدل التكرار من البيانات المتاحة</strong></p><ul><li dir="RTL">مرض السكري من النوع الثاني.</li><li dir="RTL">تورم الوجه.</li><li dir="RTL">الصداع.</li><li dir="RTL">انخفاض في مستويات الكورتيزول في دمك.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في الأطفال:</strong></p><ul><li dir="RTL">تصلب في الذراعين والساقين</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في البالغين:</strong></p><ul><li dir="RTL">زيادة الضغط داخل الجمجمة (مما يتسبب في ظهور أعراض كالصداع الشديد أو اضطرابات في الرؤية أو القيء).</li><li dir="RTL">الطفح الجلدي.</li><li dir="RTL">الحكة.</li><li dir="RTL">نتوءات بارزة مثيرة للحكة على الجلد.</li><li dir="RTL">احمرار أو حكة أو ألم في موضع الحقن.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تتكوّن أجسام مضادة لهرمون النمو الذي تم حقنه، ولكن لا يبدو أن هذه الأجسام المضادة توقف عمل هرمون النمو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تظهر بروزات أو تكتلات في الجلد المحيط بموضع الحقن، ولكن ينبغي ألا يحدث ذلك إذا قمت بالحقن في موضع مختلف كل مرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة لجينوتروبين ٥,٣ مجم: من الآثار الجانبية النادرة جدًا التي قد تحدث بسبب مادة الميتاكريزول الحافظة، التهاب العضلات القريبة من موضع الحقن. إذا أكد طبيبك إصابتك بهذا الأثر الجانبي، ينبغي عليك استخدام منتج جينوتروبين لا يحتوي على الميتاكريزول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حدثت في حالات نادرة وفاة مفاجئة لبعض المرضى المصابين بمتلازمة برادر ويلي. إلا أنه، لم يثبت وجود أي صلة بين هذه الحالات والعلاج بجينوتروبين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تعرضت لانزعاج أو ألم في الورك أو الركبة أثناء خضوعك للعلاج بجينوتروبين فقد يدرس طبيبك احتمال إصابتك بانخلاع مشاشة رأس عظم الفخذ ومرض ليج كالف بيرتيس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تتضمن الآثار الجانبية الأخرى المحتملة في أثناء علاجك بهرمون النمو، التالي: قد تتعرض أنت (أو طفلك) لارتفاع في نسبة السكر في الدم أو انخفاض في مستويات هرمون الغدة الدرقية. يمكن اختبار ذلك بواسطة طبيبك وإذا لزم الأمر فسيقوم طبيبك بوصف علاج مناسب. في حالات نادرة، تم الإبلاغ عن حدوث التهاب في البنكرياس في المرضى الذين تم علاجهم بهرمون النمو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا تعرضت لأي أعراض جانبية، فاستشر طبيبك، أو الصيدلي، أو الممرض. يتضمن ذلك أي أعراض جانبية محتملة لم يرد ذكرها في هذه النشرة. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول مأمونية هذا الدواء<strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإبلاغ عن أي عرض جانبي (أعراض جانبية):</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد: ۱۹۹۹۹</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:376px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال </em><em>ب</em><em>المؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">حتفظ بالدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم جينوتروبين بعد تاريخ انتهاء الصلاحية المُدون على العبوة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>بالنسبة لجينوتروبين ٥.٣ ملجم:</u></strong></p><p dir="RTL">يُحفظ في مُبرِّد (من ٢&deg;-&deg;٨ درجة مئوية). تُحفظ الخرطوشة ذات الحجرتين في العبوة الكرتونية الخارجية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل فتح المنتج، يُمكن إخراجه من المُبرِد دون الحاجة إلى استبداله، لمدة أقصاها شهر واحد، في درجة حرارة لا تزيد عن ٢٥ درجة مئوية، ويجب التخلص منه بعد مرور هذه المدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>بعد تحضير المحلول:</u></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>بالنسبة لجينوتروبين٥.٣ ملجم:</u></strong></p><p dir="RTL">قم بتخزينه في الثلاجة (٢ درجة مئوية - ٨ درجات مئوية) لمدة أقصاها ٤ أسابيع. لا تقم بتجميده. قم بالاحتفاظ الخرطوشة ذات الحجيرتين في علبة الأقلام حتى تحميها من الضوء.</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت احتواءه على جسيمات أو إذا كان المحلول غير صاف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تقم بتجميد جينوتروبين أو تعرضه لدرجة التجمد. إذا ما تجمد الدواء، فلا تقم باستخدامه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تقم أبدًا بالتخلص من الإبر أو من الخراطيش أو القنينات أو الأمبولات الفارغة أو المستخدمة جزئيًا، مع النفايات العادية الخاصة بك. بعد انتهائك من استخدام الإبرة، عليك التخلص منها بحرص بحيث لا يُمكن إعادة استخدامها أو التعرض للوخز بها. يمكنك الحصول على صندوق خاص &quot;للأدوات الحادة&quot; من المستشفى أو عيادة النمو التي تذهب إليه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو في المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="RTL">المادة الفعالة هي سوماتروبين*.</li><li dir="RTL">تحتوي الخرطوشة الواحدة على ٥,٣<strong> </strong>مجم من سوماتروبين*.</li><li dir="RTL">بعد التحضير، يكون تركيز سوماتروبين* ٥,٣ مجم لكل مل.</li><li dir="RTL">مكونات المسحوق الأخرى هي: جليسين (E٦٤٠) ومانيتول (E٤٢١) وفوسفات ثنائي هيدروجين الصوديوم لا مائي (E٣٣٩) وفوسفات ثنائي الصوديوم لا مائي (E٣٣٩) (انظر القسم ٢ &quot;يحتوي جينوتروبين على الصوديوم&quot;).</li><li dir="RTL">مكونات المذيب: ماء للحقن ومانيتول (E٤٢١) وميتاكريزول.</li></ul><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">*تم إنتاجها في خلايا بكتيريا <em>إيشريشيا كولاي </em>باستخدام تكنولوجيا الحمض النووي المأشوب</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">جينوتروبين ٥,٣ مجم هو مسحوق ومذيب لإعداد محلول للحقن في خرطوشة مقسمة إلى حجيرتين تحتوي على المسحوق في إحدى الحجيرتين بينما المذيب في الحجيرة الأخرى ٥,٣ مجم/مل. عبوة بحجم مخصص لخرطوشة واحدة.</p><p dir="RTL">&nbsp;<strong>&nbsp;</strong></p><p dir="RTL">المسحوق أبيض اللون والمذيب سائل شفاف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكنك استخدام الخراطيش مع أداة الحقن المتمثلة في قلم الخاصة بجينوتروبين. تكون خراطيش جينوتروبين مرمزة بالألوان ويجب أن يتم استخدامها مع قلم جينوتروبين المرمز بالألوان المقابل لها حتى يتم إعطاء الجرعة الصحيحة: يجب أن يتم استخدام خرطوشة جينوتروبين ٥,٣ مجم (الزرقاء) مع قلم جينوتروبين ٥,٣<strong> </strong>(الأزرق).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعليمات استخدام الأداة مرفقة في العبوة الخاصة بالأداة. اطلب من طبيبك أداة الحقن إذا لم تكن لديك واحدة بالفعل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك تصريح التسويق</strong></p><p dir="RTL">Pfizer SA, Boulevard de la Plaine ١٧, ١٠٥٠ Bruxelles, Belgium، بلجيكا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المصنع</strong></p><p dir="RTL">Pfizer Manufacturing Belgium NV, Rijksweg ١٢, ٢٨٧٠ Puurs Sint-Amands, Belgium</p><p dir="RTL">&nbsp;بلجيكا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                GENOTROPIN, 5.3 mg, powder and solvent for solution for injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                GENOTROPIN 5.3 mg powder and solvent for solution for injection, with preservative. One cartridge contains 5.3 mg somatropin*. After reconstitution  the concentration of somatropin is 5.3 mg/ml.
 
* produced in Escherichia coli cells by recombinant DNA technology

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection. In the two-chamber cartridge there is a white powder in the front compartment and a clear solution in the rear compartment.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Children</u></p><p>Growth disturbance due to insufficient secretion of growth hormone (growth hormone deficiency, GHD) and growth disturbance associated with Turner syndrome or chronic renal insufficiency.</p><p>&nbsp;</p><p>Growth disturbance [current height standard deviation score (SDS) &lt; - 2.5 and parental adjusted height SDS &lt; - 1] in short children born small for gestational age (SGA), with a birth weight and/or length below - 2 SD, who failed to show catch-up growth [height velocity (HV) SDS &lt; 0 during the last year] by 4 years of age or later.</p><p>&nbsp;</p><p>Prader-Willi syndrome (PWS), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing.</p><p>&nbsp;</p><p><u>Adults</u></p><p>Replacement therapy in adults with pronounced growth hormone deficiency.</p><p>&nbsp;</p><p><em>Adult Onset:</em> Patients who have severe growth hormone deficiency associated with multiple hormone deficiencies as a result of known hypothalamic or pituitary pathology, and who have at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo an appropriate dynamic test in order to diagnose or exclude a growth hormone deficiency.</p><p>&nbsp;</p><p><em>Childhood Onset:</em> Patients who were growth hormone deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes. Patients with childhood onset GHD should be re-evaluated for growth hormone secretory capacity after completion of longitudinal growth. In patients with a high likelihood for persistent GHD, i.e. a congenital cause or GHD secondary to a pituitary/hypothalamic disease or insult, an insulin-like growth factor-I (IGF-I) SDS &lt; - 2 off growth hormone treatment for at least 4 weeks should be considered sufficient evidence of profound GHD.</p><p>&nbsp;</p><p>All other patients will require IGF-I assay and one growth hormone stimulation test.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The dosage and administration schedule should be individualized.</p><p>&nbsp;</p><p>The injection should be given subcutaneously and the site varied to prevent lipoatrophy.</p><p>&nbsp;</p><p><em>Growth disturbance due to insufficient secretion of growth hormone in children: </em>Generally a dose of 0.025 - 0.035 mg/kg body weight per day or 0.7 - 1.0 mg/m&sup2; body surface area per day is recommended. Even higher doses have been used.</p><p>&nbsp;</p><p>Where childhood onset GHD persists into adolescence, treatment should be continued to achieve full somatic development (e.g. body composition, bone mass). For monitoring, the attainment of a normal peak bone mass defined as a T score &gt; - 1 (i.e. standardized to average adult peak bone mass measured by dual energy X-ray absorptiometry taking into account sex and ethnicity) is one of the therapeutic objectives during the transition period. For guidance on dosing see adult section below.</p><p>&nbsp;</p><p><em>Prader-Willi syndrome, for improvement of growth and body composition in children:</em> Generally a dose of 0.035 mg/kg body weight per day or 1.0 mg/m<sup>2</sup> body surface area per day is recommended. Daily doses of 2.7 mg should not be exceeded. Treatment should not be used in children with a growth velocity of less than 1 cm per year and near closure of epiphyses.</p><p>&nbsp;</p><p><em>Growth disturbance due to Turner syndrome:</em> A dose of 0.045 - 0.050 mg/kg body weight per day or 1.4 mg/m&sup2; body surface area per day is recommended.</p><p>&nbsp;</p><p><em>Growth disturbance in chronic renal insufficiency:</em> A dose of 0.045 - 0.050 mg/kg body weight per day (1.4 mg/m&sup2; body surface area per day) is recommended. Higher doses can be needed if growth velocity is too low. A dose correction can be needed after six months of treatment.</p><p>&nbsp;</p><p><em>Growth disturbance in short children born small for gestational age: </em>A dose of 0.035 mg/kg body weight per day (1 mg/m&sup2; body surface area per day) is usually recommended until final height is reached (see section 5.1). Treatment should be discontinued after the first year of treatment if the height velocity SDS is below + 1. Treatment should be discontinued if height velocity is &lt; 2 cm/year and, if confirmation is required, bone age is &gt; 14 years (girls) or &gt; 16 years (boys), corresponding to closure of the epiphyseal growth plates.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:593px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Dosage recommendations in Pediatric Patients</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p>mg/kg body weight</p><p>dose per day</p></td><td style="vertical-align:top"><p>mg/m&sup2; body surface area</p><p>dose per day</p></td></tr><tr><td style="vertical-align:top"><p>Growth hormone deficiency in children</p></td><td style="vertical-align:top"><p>0.025 - 0.035</p></td><td style="vertical-align:top"><p>0.7 - 1.0</p></td></tr><tr><td style="vertical-align:top"><p>Prader-Willi syndrome in children</p></td><td style="vertical-align:top"><p>0.035</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top"><p>Turner syndrome</p></td><td style="vertical-align:top"><p>0.045 - 0.050</p></td><td style="vertical-align:top"><p>1.4</p></td></tr><tr><td style="vertical-align:top"><p>Chronic renal insufficiency</p></td><td style="vertical-align:top"><p>0.045 - 0.050</p></td><td style="vertical-align:top"><p>1.4</p></td></tr><tr><td style="vertical-align:top"><p>Children born small for gestational age</p></td><td style="vertical-align:top"><p>0.035</p></td><td style="vertical-align:top"><p>1.0</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Growth hormone deficient adult patients:</em> In patients who continue growth hormone therapy after childhood GHD, the recommended dose to restart is 0.2 &ndash; 0.5 mg per day. The dose should be gradually increased or decreased according to individual patient requirements as determined by the IGF-I concentration.</p><p>&nbsp;</p><p>In patients with adult-onset GHD, therapy should start with a low dose, 0.15 &ndash; 0.3 mg per day. The dose should be gradually increased according to individual patient requirements as determined by the IGF-I concentration.</p><p>&nbsp;</p><p>In both cases treatment goal should be IGF-I concentrations within 2&nbsp;SDS from the age corrected mean. Patients with normal IGF-I concentrations at the start of the treatment should be administered growth hormone up to an IGF-I level into upper range of normal, not exceeding the 2 SDS. Clinical response and side effects may also be used as guidance for dose titration. It is recognised that there are patients with GHD who do not normalize IGF-I levels despite a good clinical response, and thus do not require dose escalation. The maintenance dose seldom exceeds 1.0 mg per day. Women may require higher doses than men, with men showing an increasing IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement are under-treated while men are over-treated. The accuracy of the growth hormone dose should therefore be controlled every 6 months. As normal physiological growth hormone production decreases with age, dose requirements are reduced. In patients above 60 years, therapy should start with a dose of 0.1 - 0.2 mg per day and should be slowly increased according to individual patient requirements. The minimum effective dose should be used. The maintenance dose in these patients seldom exceeds 0.5 mg per day.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Somatropin must not be used when there is any evidence of activity of a tumour. Intracranial tumours must be inactive and antitumour therapy must be completed prior to starting growth hormone therapy. Treatment should be discontinued if there is evidence of tumour growth.

GENOTROPIN should not be used for growth promotion in children with closed epiphyses.

Patients with acute critical illness suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure or similar conditions should not be treated with GENOTROPIN (regarding patients undergoing substitution therapy, see section 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Diagnosis and therapy with GENOTROPIN should be initiated and monitored by physicians who are appropriately qualified and experienced in the diagnosis and management of patients with the therapeutic indication of use.</p><p>&nbsp;</p><p>Myositis is a very rare adverse event that may be related to the preservative metacresol. In the case of myalgia or disproportionate pain at injection site, myositis should be considered and if confirmed, a GENOTROPIN presentation without metacresol should be used.</p><p>&nbsp;</p><p>The maximum recommended daily dose should not be exceeded (see section 4.2).</p><p>&nbsp;</p><p><u>Insulin sensitivity</u></p><p>Somatropin may reduce insulin sensitivity. For patients with diabetes mellitus, the insulin dose may require adjustment after somatropin therapy is instituted. Patients with diabetes, glucose intolerance, or additional risk factors for diabetes should be monitored closely during somatropin therapy.</p><p>&nbsp;</p><p><u>Thyroid function</u></p><p>Growth hormone increases the extrathyroidal conversion of T4 to T3 which may result in a reduction in serum T4 and an increase in serum T3 concentrations. Whereas the peripheral thyroid hormone levels have remained within the reference ranges in the majority of healthy subjects, hypothyroidism theoretically may develop in subjects with subclinical hypothyroidism. Consequently, monitoring of thyroid function should therefore be conducted in all patients. In patients with hypopituitarism on standard replacement therapy, the potential effect of growth hormone treatment on thyroid function must be closely monitored.</p><p>&nbsp;</p><p><u>Hypoadrenalism</u></p><p>Introduction of somatropin treatment may result in inhibition of 11&beta;HSD-1 and reduced serum cortisol concentrations. In patients treated with somatropin, previously undiagnosed central (secondary) hypoadrenalism may be unmasked and glucocorticoid replacement may be required. In addition, patients treated with glucocorticoid replacement therapy for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses, following initiation of somatropin treatment (see section 4.5).</p><p>&nbsp;</p><p><u>Use with oral oestrogen therapy</u></p><p>If a woman taking somatropin begins oral oestrogen therapy, the dose of somatropin may need to be increased to maintain the serum IGF-1 levels within the normal age-appropriate range. Conversely, if a woman on somatropin discontinues oral oestrogen therapy, the dose of somatropin may need to be reduced to avoid excess of growth hormone and/or side effects (see section 4.5).</p><p>&nbsp;</p><p>In growth hormone deficiency secondary to treatment of malignant disease, it is recommended to pay attention to signs of relapse of the malignancy. In childhood cancer survivors, an increased risk of a second neoplasm has been reported in patients treated with somatropin after their first neoplasm. Intracranial tumours, in particular meningiomas, in patients treated with radiation to the head for their first neoplasm, were the most common of these second neoplasms.</p><p>&nbsp;</p><p>In patients with endocrine disorders, including growth hormone deficiency, slipped epiphyses of the hip may occur more frequently than in the general population. Children limping during treatment with somatropin, should be examined clinically.</p><p>&nbsp;</p><p><u>Benign intracranial hypertension</u></p><p>In case of severe or recurrent headache, visual problems, nausea and/or vomiting, a funduscopy for papilloedema is recommended. If papilloedema is confirmed, a diagnosis of benign intracranial hypertension should be considered and, if appropriate, the growth hormone treatment should be discontinued. At present there is insufficient evidence to give specific advice on the continuation of growth hormone treatment in patients with resolved intracranial hypertension. If growth hormone treatment is restarted, careful monitoring for symptoms of intracranial hypertension is necessary.</p><p>&nbsp;</p><p><u>Leukaemia</u></p><p>Leukaemia has been reported in a small number of growth hormone deficiency patients, some of whom have been treated with somatropin. However, there is no evidence that leukaemia incidence is increased in growth hormone recipients without predisposition factors.</p><p>&nbsp;</p><p><u>Antibodies</u></p><p>As with all somatropin containing products, a small percentage of patients may develop antibodies to GENOTROPIN. GENOTROPIN has given rise to the formation of antibodies in approximately 1% of patients. The binding capacity of these antibodies is low and there is no effect on growth rate. Testing for antibodies to somatropin should be carried out in any patient with otherwise unexplained lack of response.</p><p>&nbsp;</p><p><u>Elderly patients</u></p><p>Experience in patients above 80 years is limited. Elderly patients may be more sensitive to the action of GENOTROPIN, and therefore may be more prone to develop adverse reactions.</p><p>&nbsp;</p><p><u>Acute critical illness</u></p><p>The effects of GENOTROPIN on recovery were studied in two placebo controlled trials involving 522 critically ill adult patients suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma or acute respiratory failure. Mortality was higher in patients treated with 5.3 or 8 mg GENOTROPIN daily compared to patients receiving placebo, 42% vs. 19%. Based on this information, these types of patients should not be treated with GENOTROPIN. As there is no information available on the safety of growth hormone substitution therapy in acutely critically ill patients, the benefits of continued treatment in this situation should be weighed against the potential risks involved.</p><p>&nbsp;</p><p>In all patients developing other or similar acute critical illness, the possible benefit of treatment with Genotropin must be weighed against the potential risk involved.</p><p>&nbsp;</p><p><u>Pancreatitis</u></p><p>Although rare, pancreatitis should be considered in somatropin-treated patients, especially children who develop abdominal pain.</p><p><u>&nbsp;</u></p><p><u>Prader-Willi syndrome</u></p><p>In patients with Prader-Willi syndrome, treatment should always be in combination with a calorie-restricted diet.</p><p>&nbsp;</p><p>There have been reports of fatalities associated with the use of growth hormone in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity (those patients exceeding a weight/height of 200 %), history of respiratory impairment or sleep apnoea, or unidentified respiratory infection. Patients with one or more of these factors may be at increased risk.</p><p>&nbsp;</p><p>Before initiation of treatment with somatropin in patients with Prader-Willi syndrome, signs for upper airway obstruction, sleep apnoea, or respiratory infections should be assessed.</p><p>&nbsp;</p><p>If during the evaluation of upper airway obstruction, pathological findings are observed, the child should be referred to an Ear, nose and throat (ENT) specialist for treatment and resolution of the respiratory disorder prior to initiating growth hormone treatment.</p><p>&nbsp;</p><p>Sleep apnoea should be assessed before onset of growth hormone treatment by recognised methods such as polysomnography or overnight oxymetry, and monitored if sleep apnoea is suspected.</p><p>&nbsp;</p><p>If during treatment with somatropin patients show signs of upper airway obstruction (including onset of or increased snoring), treatment should be interrupted, and a new ENT assessment performed.</p><p>&nbsp;</p><p>All patients with Prader-Willi syndrome should be monitored if sleep apnoea is suspected.</p><p>&nbsp;</p><p>Patients should be monitored for signs of respiratory infections, which should be diagnosed as early as possible and treated aggressively.</p><p>&nbsp;</p><p>All patients with Prader-Willi syndrome should also have effective weight control before and during growth hormone treatment.</p><p>&nbsp;</p><p>Scoliosis is common in patients with Prader-Willi syndrome. Scoliosis may progress in any child during rapid growth. Signs of scoliosis should be monitored during treatment.</p><p>&nbsp;</p><p>Experience with prolonged treatment in adults and in patients with Prader-Willi syndrome is limited.</p><p>&nbsp;</p><p><u>Small for gestational age</u></p><p>In short children born SGA other medical reasons or treatments that could explain growth disturbance should be ruled out before starting treatment.</p><p>&nbsp;</p><p>In SGA children it is recommended to measure fasting insulin and blood glucose before start of treatment and annually thereafter. In patients with increased risk for diabetes mellitus (e.g. familial history of diabetes, obesity, severe insulin resistance, acanthosis nigricans) oral glucose tolerance testing (OGTT) should be performed. If overt diabetes occurs, growth hormone should not be administered.</p><p>&nbsp;</p><p>In SGA children it is recommended to measure the IGF-I level before start of treatment and twice a year thereafter. If on repeated measurements IGF-I levels exceed +2 SD compared to references for age and pubertal status, the IGF-I / IGFBP-3 ratio could be taken into account to consider dose adjustment.</p><p>&nbsp;</p><p>Experience in initiating treatment in SGA patients near onset of puberty is limited. It is therefore not recommended to initiate treatment near onset of puberty. Experience in patients with Silver-Russell syndrome is limited.</p><p>&nbsp;</p><p>Some of the height gain obtained with treating short children born SGA with growth hormone may be lost if treatment is stopped before final height is reached.</p><p>&nbsp;</p><p><u>Chronic renal insufficiency</u></p><p>In chronic renal insufficiency, renal function should be below 50 percent of normal before institution of therapy. To verify growth disturbance, growth should be followed for a year preceding institution of therapy. During this period, conservative treatment for renal insufficiency (which includes control of acidosis, hyperparathyroidism and nutritional status) should have been established and should be maintained during treatment. The treatment should be discontinued at renal transplantation.</p><p>&nbsp;</p><p>To date, no data on final height in patients with chronic renal insufficiency treated with Genotropin are available.</p><p><u>Sodium content</u></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose. Patients on low sodium diets can be informed that this medicinal product is essentially &lsquo;sodium free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant treatment with glucocorticoids inhibits the growth-promoting effects of somatropin containing products. Patients with Adrenocorticotropic hormone (ACTH) deficiency should have their glucocorticoid replacement therapy carefully adjusted to avoid any inhibitory effect on growth. Therefore, patients treated with glucocorticoids should have their growth monitored carefully to assess the potential impact of glucocorticoid treatment on growth.</p><p>&nbsp;</p><p>Growth hormone decreases the conversion of cortisone to cortisol and may unmask previously undiscovered central hypoadrenalism or render low glucocorticoid replacement doses ineffective (see section 4.4).</p><p>&nbsp;</p><p>Data from an interaction study performed in growth hormone deficient adults, suggests that somatropin administration may increase the clearance of compounds known to be metabolised by cytochrome P450 isoenzymes. The clearance of compounds metabolised by cytochrome P 450 3A4 (e.g. sex steroids, corticosteroids, anticonvulsants and ciclosporin) may be especially increased resulting in lower plasma levels of these compounds. The clinical significance of this is unknown.</p><p>&nbsp;</p><p>Also see section 4.4 for statements regarding diabetes mellitus and thyroid disorder.</p><p>&nbsp;</p><p>In women on oral oestrogen replacement, a higher dose of growth hormone may be required to achieve the treatment goal (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy</em></p><p>Animal studies are insufficient with regard to effects on pregnancy, embryofoetal development, parturition or postnatal development (See section 5.3). No clinical studies on exposed pregnancies are available. Therefore, somatropin containing products are not recommended during pregnancy and in women of childbearing potential not using contraception.</p><p>&nbsp;</p><p>Breats-feeding</p><p>There have been no clinical studies conducted with somatropin containing products in breast-feeding women. It is not known whether somatropin is excreted in human milk, but absorption of intact protein from the gastrointestinal tract of the infant is extremely unlikely. Therefore caution should be exercised when somatropin containing products are administered to breast-feeding women.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>GENOTROPIN has no influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients with growth hormone deficiency are characterized by extracellular volume deficit. When treatment with somatropin is started this deficit is rapidly corrected. In adult patients adverse effects related to fluid retention, such as oedema peripheral, face oedema, musculoskeletal stiffness, arthralgia, myalgia and paraesthesia are common. In general these adverse effects are mild to moderate, arise within the first months of treatment and subside spontaneously or with dose-reduction.</p><p>&nbsp;</p><p>The incidence of these adverse effects is related to the administered dose, the age of patients, and possibly inversely related to the age of patients at the onset of growth hormone deficiency. In children such adverse effects are uncommon.</p><p>&nbsp;</p><p>Genotropin has given rise to the formation of antibodies in approximately 1 % of the patients. The binding capacity of these antibodies has been low and no clinical changes have been associated with their formation, see section 4.4.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Table 1 shows the adverse reactions ranked under headings of System Organ Class and frequency for children and adults, using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><thead><tr><td colspan="7" style="vertical-align:top"><br /><br />&nbsp;<p><strong>Table</strong><strong> 1:</strong><strong> Tabulated list of adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common (&ge;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge;1/100 to &lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge;1/1,000 to &lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge;1/10,000 to &lt;1/1000)</strong></p></td><td style="vertical-align:top"><p><strong>Very rare (&lt;1/10,000)</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p><p><strong>(cannot be estimated from available data)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant, and unspecified (including cysts and polyps)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(Children) Leukaemia<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(Adults and Children)</p><p>Type&nbsp;2 diabetes mellitus</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(Adults) Paraesthesia*</p><p>&nbsp;</p><p>(Adults) Carpal tunnel syndrome</p></td><td style="vertical-align:top"><p>(Children) Benign intracranial hypertension</p><p>&nbsp;</p><p>(Children) Paraesthesia*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(Adults) Benign intracranial hypertension</p><p>&nbsp;</p><p>(Adults and Children)</p><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(Children) Rash**, Pruritus**, Urticaria**</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(Adults) Rash**, Pruritus**, Urticaria**</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>(Adults) Arthralgia*</p></td><td style="vertical-align:top"><p>(Adults) Myalgia*</p><p>&nbsp;</p><p>(Adults)</p><p>Musculoskeletal stiffness*</p><p>&nbsp;</p><p>(Children) Arthralgia*</p></td><td style="vertical-align:top"><p>(Children) Myalgia*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(Children) Musculoskeletal stiffness*</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(Adults and Children)</p><p>Gynaecomastia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>(Adults) Oedema peripheral*</p></td><td style="vertical-align:top"><p>(Children) Injection-site reaction<sup>$</sup></p></td><td style="vertical-align:top"><p>(Children) Oedema peripheral*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(Adults and Children)</p><p>Face oedema*</p><p>&nbsp;</p><p>(Adults) Injection‑site reaction<sup>$</sup></p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(Adults and Children)</p><p>Blood cortisol decreased<sup>&Dagger;</sup></p></td></tr></tbody></table><p>* In general, these adverse effects are mild to moderate, arise within the first months of treatment, and subside spontaneously or with dose-reduction. The incidence of these adverse effects is related to the administered dose, the age of the patients, and possibly inversely related to the age of the patients at the onset of growth hormone deficiency.<sup> </sup></p><p>** Adverse Drug Reactions (ADR) identified post-marketing.</p><p>$ Transient injection site reactions in children have been reported.</p><p>&Dagger; Clinical significance is unknown.</p><p>&dagger; Reported in growth hormone deficient children treated with somatropin, but the incidence appears to be similar to that in children without growth hormone deficiency.</p><p>&nbsp;</p><p><u>Reduced serum cortisol levels </u></p><p>Somatropin has been reported to reduce serum cortisol levels, possibly by affecting carrier proteins or by increased hepatic clearance. The clinical relevance of these findings may be limited. Nevertheless, corticosteroid replacement therapy should be optimised before initiation of GENOTROPIN therapy.</p><p>&nbsp;</p><p><u>Prader-Willi syndrome </u></p><p>In the post-marketing experience rare cases of sudden death have been reported in patients affected by Prader-Willi syndrome treated with somatropin, although no causal relationship has been demonstrated.</p><p>&nbsp;</p><p><u>Leukaemia</u></p><p>Cases of leukaemia have been reported in children with a GH deficiency, some of whom were treated with somatropin and included in the post-marketing experience. <u>However, there is no evidence of an increased risk of leukaemia without predisposition factors, such as radiation to the brain or head.</u></p><p>&nbsp;</p><p><u>Slipped capital femoral epiphysis and Legg-Calve-Perthes disease</u></p><p>Slipped capital femoral epiphysis and Legg-Calve-Perthes disease have been reported in children treated with GH. Slipped capital femoral epiphysis occurs more frequently in case of endocrine disorders and Legg-Calve-Perthes is more frequent in case of short stature. But, it is unknown if these 2 pathologies are more frequent or not while treated with somatropin. Their diagnosis should be considered in a child with a discomfort or pain in the hip or knee.</p><p>&nbsp;</p><p><u>Other adverse drug reactions</u></p><p>Other adverse drug reactions may be considered somatropin class effects, such as possible hyperglycaemia caused by decreased insulin sensitivity, decreased free thyroxin level and benign intra-cranial hypertension.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions </u></p><p>Reporting suspected adverse reactions after marketing authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to National Pharmacovigilance Center (NPC).</p><p><br /><strong>To Report side effect(s):</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong><br />&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:348px"><tbody><tr><td style="vertical-align:top"><p><strong>The National Pharmacovigilance Center (NPC):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>Acute overdosage could lead initially to hypoglycaemia and subsequently to hyperglycaemia.</p><p>&nbsp;</p><p>Long-term overdosage could result in signs and symptoms consistent with the known effects of human growth hormone excess.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anterior pituitary lobe hormones and analogues, ATC code: H01A C01</p><p>&nbsp;</p><p>Somatropin is a potent metabolic hormone of importance for the metabolism of lipids, carbohydrates and proteins. In children with inadequate endogenous growth hormone, somatropin stimulates linear growth and increases growth rate. In adults, as well as in children, somatropin maintains a normal body composition by increasing nitrogen retention and stimulation of skeletal muscle growth, and by mobilization of body fat. Visceral adipose tissue is particularly responsive to somatropin. In addition to enhanced lipolysis, somatropin decreases the uptake of triglycerides into body fat stores. Serum concentrations of IGF-I and IGFBP-3 (Insulin-like Growth Factor Binding Protein 3) are increased by somatropin.</p><p>&nbsp;</p><p>In addition, the following actions have been demonstrated:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lipid metabolism: Somatropin induces hepatic LDL cholesterol receptors, and affects the profile of serum lipids and lipoproteins. In general, administration of somatropin to growth hormone deficient patients results in reductions in serum LDL and apolipoprotein B. A reduction in serum total cholesterol may also be observed.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carbohydrate metabolism: Somatropin increases insulin but fasting blood glucose is commonly unchanged. Children with hypopituitarism may experience fasting hypoglycemia. This condition is reversed by somatropin.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Water and mineral metabolism: Growth hormone deficiency is associated with decreased plasma and extracellular volumes. Both are rapidly increased after treatment with somatropin. Somatropin induces the retention of sodium, potassium and phosphorus.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bone metabolism: Somatropin stimulates the turnover of skeletal bone. Long-term administration of somatropin to growth hormone deficient patients with osteopenia results in an increase in bone mineral content and density at weight-bearing sites.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Physical capacity: Muscle strength and physical exercise capacity are improved after long-term treatment with somatropin. Somatropin also increases cardiac output, but the mechanism has yet to be clarified. A decrease in peripheral vascular resistance may contribute to this effect.</p><p>&nbsp;</p><p>In clinical trials in short children born SGA doses of 0.033 and 0.067 mg/kg body weight per day have been used for treatment until final height. In 56 patients who were continuously treated and have reached (near) final height, the mean change from height at start of treatment was +1.90 SDS (0.033&nbsp;mg/kg body weight per day) and +2.19 SDS (0.067 mg/kg body weight per day). Literature data from untreated SGA children without early spontaneous catch-up suggest a late growth of 0.5&nbsp;SDS.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Absorption</em><br />The bioavailability of subcutaneously administered somatropin is approximately 80 % in both healthy subjects and growth hormone deficient patients. A subcutaneous dose of 0.035 mg/kg of somatropin results in plasma C<sub>max</sub> and t<sub>max</sub> values in the range of 13-35 ng/ml and 3-6 hours respectively.</p><p>&nbsp;</p><p><em>Elimination</em><br />The mean terminal half-life of somatropin after intravenous administration in growth hormone deficient adults is about 0.4 hours. However, after subcutaneous administration, half-lives of 2-3 hours are achieved. The observed difference is likely due to slow absorption from the injection site following subcutaneous administration.</p><p>&nbsp;</p><p><em>Sub-populations</em></p><p>The absolute bioavailability of somatropin seems to be similar in males and females following s.c.&nbsp;administration.</p><p>&nbsp;</p><p>Information about the pharmacokinetics of somatropin in geriatric and paediatric populations, in different races and in patients with renal, hepatic or cardiac insufficiency is either lacking or incomplete.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In studies regarding general toxicity, local tolerance and reproduction toxicity no clinically relevant effects have been observed.</p><p>&nbsp;</p><p>In vitro and in vivo genotoxicity studies on gene mutations and induction of chromosome aberrations have been negative.</p><p>&nbsp;</p><p>An increased chromosome fragility has been observed in one in-vitro study on lymphocytes taken from patients after long term treatment with somatropin and following the addition of the radiomimetic drug bleomycin.The clinical significance of this finding is unclear.</p><p>&nbsp;</p><p>In another study, no increase in chromosomal abnormalities was found in the lymphocytes of patients who had received long term somatropin therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Powder (front compartment):</u></p><p>Glycine (E640) : 2.3 mg</p><p>Sodium dihydrogen phosphate anhydrous (E339) : 0.33 mg</p><p>Disodium phosphate anhydrous (E339) : 0.32 mg</p><p>Mannitol (E421) : 1.8 mg</p><p><u>Solvent (rear compartment):</u></p><p>Water for injections: To 1.14 ml</p><p>Mannitol (E421): 45mg</p><p>Metacresol 3.4 mg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years

Presentation (for a list of presentations, 
see section 2)	Shelf life after reconstitution
	
	Chemical and physical in-use stability has been demonstrated for 28 days at 2C - 8C.

From a microbiological point of view, once reconstituted, the product may be stored for 28 days at 2C - 8C. Other in-use storage times and conditions are the responsibility of the user.

Do not use GENOTROPIN after the expiry date which is stated on the carton after EXP:. The expiry date refers to the last day of that month.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Before reconstitution</u></p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C), or for a maximum of 1 month at or below 25&deg;C. Keep the vial and ampoule/two-chamber cartridge in the outer carton in order to protect from light.</p><p>&nbsp;</p><p><u>After reconstitution</u></p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze. Keep the vial/two-chamber cartridge in the outer carton in order to protect from light. For storage conditions of the reconstituted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:633px"><tbody><tr><td style="vertical-align:top"><p><strong>Presentation </strong></p><p><strong>(for a list of presentations, see section 2)</strong></p></td><td style="vertical-align:top"><p><strong>Container</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Powder and 1 ml solvent in a two-chamber glass cartridge (type I glass) separated by a rubber plunger (bromobutyl). The cartridge is sealed at one end with a rubber disc (bromobutyl) and an aluminium cap and at the other end by a rubber stopper (bromobutyl). The two-chamber cartridge is supplied for use in a re‑usable injection device GENOTROPIN Pen</p><p>&nbsp;</p><p>The GENOTROPIN Pens are colour coded, and must be used with the matching colour coded GENOTROPIN two-chamber cartridge to give the correct dose.</p><p>The GENOTROPIN Pen 5.3 (blue) must be used with GENOTROPIN 5.3&nbsp;mg cartridge (blue).</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:633px"><tbody><tr><td style="vertical-align:top"><p><strong>Presentation </strong></p><p><strong>(for a list of presentations, see section 2)</strong></p></td><td style="vertical-align:top"><p><strong>Package size</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1x5.3 mg, 5x5.3 mg,</p><p>1x5.3 mg pre-filled pen,</p><p>5x5.3 mg pre-filled pens</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Keep out of the sight and reach of children.</strong></p><p>&nbsp;</p><p>Only reconstitute the powder with the solvent supplied.</p><p>&nbsp;</p><p><em>Two-chamber cartridge</em>:The solution is prepared by screwing the reconstitution device or injection device sections together so that the solvent will be mixed with the powder in the two chamber cartridge. Gently dissolve the powder with a slow, swirling motion. Do not shake vigorously, this might cause denaturation of the active substance. The reconstituted solution is almost colourless or slightly opalescent. The reconstituted solution for injection is to be inspected prior to use and only clear solutions without particles should be used.</p><p>&nbsp;</p><p>Comprehensive instructions for the preparation and administration of the reconstituted Genotropin product are given in the package leaflet, section 3, &ldquo;Injecting genotropin&rdquo; and in the relevant Instructions for Use provided with the device being used.</p><p>&nbsp;</p><p>When using an injection device the injection needle should be screwed on before reconstitution.</p><p>&nbsp;</p><p><strong>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pfizer SA, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium

MANUFACTURING BY
	Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs-Sint-Amands, Belgium


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>